Cardiovascular diseases (CVDs), like many other chronic diseases, are closely related to lifestyle, mental health, and quality of life, which can lead to other diseases if not controlled (
1). In 2016, according to the World Health Organization (WHO), CVDs accounted for 56.9% of 15.2 million deaths, i.e., almost one in three (
2). Also, the prevalence of CVDs is higher in the Middle East than in other parts of the world (
3). Epidemiological studies in Iran and the United Arab Emirates indicated that the prevalence of CVDs will reach 5.9% (
4). Lifestyle alteration has led to the widespread prevalence of obesity and overweight, which is the most important risk factor for CVDs (
5,
6). According to the literature, physical activity level (PAL) and exercise are simple and low-cost non-pharmacological interventions to prevent risk factors for CVD and improve the quality of life of CVD patients (
7). Studies have shown that increased PAL reduces the inflammatory biomarkers and CVD risk factors (
8,
9). On the other hand, in late December 2019, the first variant of the new coronavirus, COVID-19, was identified (
10). According to the literature, age and underlying diseases, including hypertension, diabetes, CVD, etc., are closely related to the severity of COVID-19 and the occurrence of the acute respiratory syndrome (
11,
12). The low PAL induced by COVID-19 quarantine increases the risk factors for CVDs (
13). Until finding a definitive cure, strengthening the immune system is one way to prevent or minimize the adverse effects of COVID-19, which can be achieved by promoting PAL (
14). Exercise has positive effects on the immune system and has been shown to decrease the negative effects of COVID-19 quarantine on the immune system. Regular exercise not only increases the ability to perform daily tasks and functional capacity but also strengthens the immune system of CVD patients (
15,
16). Due to the novelty of the coronavirus, so far, limited scientific studies have evaluated the effect of exercise on COVID-19, particularly in CVD patients.